GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.04 (+0.06%)

Growth Price

Undervalued by 126.09%

Stability Price

Overvalued by 29.18%

Company Metrics

  • P/E 6.73
  • P/S 3023.69
  • P/B 5.68
  • EPS 10.81
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.88 / 2.6%
  • Avg. Vol. 9.58M
  • Shares 1.52B
  • Market Cap. 95528.74B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Gilead Sciences Inc.'s Worst Moves in 2016
Motley Fool - Dec 6, 2016
As 2016 draws to a close, we all tend to look back on the good and the bad experienced during another trip around the sun. Unfortunately for Gilead Sciences (NASDAQ:GILD), there were plenty of bad things that happened this year. Some of the bad news ...
Gilead Sciences Inc. (NASDAQ:GILD) Earns Consensus Hold Rating - Review Fortune
Gilead Sciences, Inc. (NASDAQ:GILD) Analytical Report - The Newburgh Press
Gilead Sciences, Inc.'s $10 Billion Mistake
Fox Business - Dec 1, 2016
Data source: Gilead Sciences. *ASR includes a predetermined discount. With Gilead's share price closing under $74 on Wednesday, those purchases aren't looking like too good of an investment at the moment.
Biotech news that matter for investors: Gilead Sciences Inc. (NASDAQ:GILD ... - The Voice Registrar
Analysts Price Target Prospective about GILEAD SCIENCES, INC. (GILD) to strike ... - Hot Stocks Point
Biotech Stocks Worth Chasing: Gilead Sciences Inc. (GILD), Heat Biologics, Inc ...
The Independent Republic - 9 hours ago
Gilead Sciences Inc. (GILD) ended last trading session with a change of 0.15 percent. It trades at an average volume of 9.6M shares versus 8.7M shares recorded at the end of last trading session.
3 Potential Acquisition Targets for Gilead Sciences, Inc.
Motley Fool - Nov 16, 2016
Gilead Sciences (NASDAQ:GILD) is looking to make a deal. That's basically what the biotech's executives said in Gilead's third-quarter earnings call on Nov 1. Which companies might be good acquisition targets for Gilead?
Gilead Sciences, Inc. (GILD): Undervalued with Lots of Growth Potential - Smarter Analyst
GILD Stock: New Revolutionary Drugs To Drive Gilead Sciences, Inc.(GILD) - Amigobulls
what are Analysts report about: Gilead Sciences Inc. (NASDAQ:GILD)
News Oracle - 8 hours ago
Gilead Sciences Inc. (NASDAQ:GILD) will report its next earnings on Jan 31 - Feb 6 (Est.). The company reported the earnings of $2.75/Share in the last quarter where the estimated EPS by analysts was $2.86/share.
Gilead Sciences Inc. (GILD) Position Cut by Arizona State Retirement System
The Cerbat Gem - Dec 6, 2016
Gilead Sciences logo Arizona State Retirement System reduced its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 0.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
Research Report for: Gilead Sciences Inc. (NASDAQ:GILD) - News Oracle
Gilead Sciences Inc. (GILD) Shares Sold by Osborn Rohs Williams & Donohoe Ltd - BBNS
Better Buy: Gilead Sciences Inc. vs. Pfizer Inc.
Motley Fool - Nov 9, 2016
Gilead Sciences (NASDAQ:GILD), for example, gave investors five times the returns of Pfizer (NYSE:PFE) over the past five years.
Gilead Sciences, Inc.: Is GILD Stock a Top Dividend Growth Stock? - Income Investors
Mizuho Initiates Buy on Gilead Sciences, Inc. (GILD); Sees 19% Upside for the ... - Smarter Analyst
Gilead Sciences Inc.: Why Investors Shouldn't Ignore GILD Stock
Income Investors - Nov 25, 2016
Gilead Sciences, Inc.(NASDAQ:GILD) stock is one that should be considered by income investors. The name of the company may not be familiar to income investors, and I don't blame you for that.
Will Gilead Sciences, Inc. (GILD) Efforts Bring it Out In The Green? - TCC
Gilead Sciences, Inc. (NASDAQ:GILD) Performance Analysis - The Newburgh Press
Parsing Liver Therapy Perspectives: Gilead And Enanta
Seeking Alpha - Dec 5, 2016
Gilead and Enanta look at the world from vastly different perspectives despite each having major revenue sources (HCV therapies) and important pipeline candidates (HBV and NASH) that are identical.
Trade of the Day: Gilead Sciences, Inc. (GILD) Stock Looks Like a Bargain - Nov 30, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) - On Nov. 1, Standard & Poor's Capital IQ lowered their target by $20 to $105 on Gilead; however, they kept their strongest buy rating, a five-star “buy” on the stock with a “next 12-months EPS estimate of $11.36.
Gilead Sciences, Inc.: Why GILD Stock Is A Value Of The Month - BNL Finance (press release) (registration) (blog)
Gilead Sciences: Negatives Overdone - Seeking Alpha